Guerbet (GBT) to sale its pharmaceutical site in Montreal (Canada) to MedXL

Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes.

The Montreal industrial facility specializes on the one hand in filling and finishing of contrast media and on the other in the large-series manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production, carried out previously in Montreal, to its pharmaceutical sites in France and the USA.

Guerbet sells this site as part of its plans to optimize its industrial network. The operation will make Guerbet more competitive by improving capacity utilization at its other manufacturing sites.

Guerbet is very happy about this transaction with MedXL, under which all 240 of its employees will keep their job. MedXL will use the Montreal site to step up its development in response to the structural growth of the sterile pre-filled syringes market.